| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Urology Research Laboratory [K. T., A. v. B., C. F. J. J., M. J. G. B., J. A. S.] and Department of Pathology [G. J. L. H. v. L., E. T. G. R.], University Hospital Nijmegen, 6500 HB Nijmegen, the Netherlands
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Recently, a number of papers have been published that describe the
inappropriate expression of nonepithelial cadherins by epithelial cells
as a putative novel mechanism for promoting the interaction with the
stroma, thereby facilitating invasion and metastasis
(13, 14, 15, 16)
. Indeed, we were able to show that human prostate
cancer cell lines, which lack expression of either E-cadherin or the
catenins and, therefore, lack an E-cadherin-mediated cell-cell
adhesion, show expression of several other cadherins (17)
.
Most prominent is the expression of the mesenchymal N-cadherin and
cadherin-11 in these cell lines. Moreover, in other epithelial-tissue
derived cancer cell lines, e.g., human bladder, melanoma,
and breast cancer cell lines (15
, 16
, 18, 19, 20)
, which lack
functional E-cadherin-mediated adhesion, expression of other cadherins
is observed. Considering that the de novo expression of
N-cadherin and cadherin-11 may distinguish changes in
cell-adhesion processes that are important for the invasive and
metastatic capacity of the prostate cancer cells, we decided to
investigate the expression of N-cadherin and cadherin-11 in human
prostate cancer specimens by single- and two-parameter
immunofluorescence. By analyzing the protein expression patterns of
these cadherins and correlating them to the expression patterns of
E-cadherin or 
-catenin, we aimed at establishing the pathological
role of induced expression of N-cadherin and cadherin-11 in prostate
cancer progression.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Immunofluorescence.
Sections were fixed using paraformaldehyde (3%) for E-cadherin,
N-cadherin, cadherin-11, and -catenin staining. On preincubation
with normal sheep serum (diluted 1:20 in PBS) for 30 min.; the
sections were incubated for 1 h with the primary antibody. Next,
the sections were incubated with biotin-labeled secondary antibody,
followed by a streptavidin-fluorescein detection step (Amersham).
Antibodies against E-cadherin [HECD-1 (mouse monoclonal antibody,
Takara)] and N-cadherin [GC4 (mouse monoclonal antibody, Sigma)], an
N-cadherin rabbit polyclonal antibody (Takara), cadherin-11 mouse
monoclonal antibody (Ref. 17
, clone No.16a), and a
rabbit polyclonal antibody against -catenin, C2081 (Sigma), were
used at a dilution of 1:100, 1:30, 1:30, 1:100, and 1:1000,
respectively.
Specificity of the antibodies against N-cadherin and Cadherin-11 was determined by the comparison of steady-state mRNA levels assessed by Northern analysis with immunofluorescence, using a panel of cell lines (17) . There was a full correlation between mRNA and immunofluorescence results. Moreover, Western analysis using these antibodies identified proteins of the expected MW (Mr 135,000 for N-cadherin (17) and Mr 120,000 for Cadherin-11.
N-cadherin, cadherin-11, and E-cadherin staining using the mouse monoclonal antibodies was performed for all of the samples and scored by three independent observers (K. T., A. v. B., and E. T. G. R.). E-cadherin was scored as either normal (membrane staining) or aberrant (negative or heterogeneous staining) as previously described by Schipper et al. (22) and Umbas et al. (23) . N-cadherin staining was judged negative when <5% of the prostate cells were positive for N-cadherin, or when no significant N-cadherin staining was observed. N-cadherin staining was considered positive when 61 5% of the prostate cancer cells showed expression. Furthermore, the staining pattern was scored, i.e., membranous, or dotted. Cadherin-11 staining was scored negative when weak diffuse staining was observed, particularly in the stroma surrounding cancer cells, or when no significant staining was observed. Cadherin-11 staining was considered positive when 61 5% of the prostate cancer cells showed expression, typically in a dotted pattern.
Double staining, using FITC- and
TRITC2
-labeled secondary antibodies were performed to investigate relative
localization of E-cadherin and N-cadherin (rabbit polyclonal) and
-catenin and cadherin-11. The samples were visualized by either
standard epiluminescence fluorescence microscopy (Zeiss,
axioscop) using the appropriate filter combinations or CSLM
(Leitz DMIRBE, Leica).
Statistical Analyses.
The 
2 test was used to determine the
correlation between staining and Gleason score. The odds ratio was used
to determine the correlation of N-cadherin or cadherin-11 with
E-cadherin.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-catenin complexes (17)
. In
particular, N-cadherin and cadherin-11, the expression of which was
confirmed by Western blot analysis, seemed to be of potential relevance
for prostate cancer progression. To gain insight into the role of
N-cadherin and cadherin-11 in human prostate cancer progression, we
used immunofluorescence analysis to study the expression patterns of
these cadherins in human primary and metastatic prostate cancer. In nonmalignant preexisting acini, we never found expression of N-cadherin, i.e., none of the 12 samples analyzed showed positive staining. For cadherin-11, we occasionally found a very weak diffuse staining in the stromal cells, which is in agreement with the putative mesenchymal nature of cadherin-11 (13) .
In cancer specimens, particularly high-grade (Gleason score: >7;
see next section on "Increased Expression ... "), we found
expression of N-cadherin in the carcinoma cells (Fig. 1, A, D, and G)
. In the primary cancer
specimens, the expression pattern is heterogeneous, with a predominant
expression at the membrane (Fig. 1, A and D)
.
Interestingly, in the high-grade tumors, N-cadherin was expressed more
homogeneously, and, moreover, the pattern of staining changed from a
membranous honeycomb-like staining to a dotted pattern (Fig. 1D)
. Because we performed double-label immunofluorescence
(FITC for N-cadherin and TRITC for E-cadherin), we were able to study
the expression of both cadherins simultaneously. On comparison of the
individual fluorescent dyes, it became evident that, in the
heterogeneously staining primary tumors, the pattern of staining was
complementary, i.e., cells showed either a predominant
expression of E-cadherin or N-cadherin at the membrane (Fig. 1A versus 1B
, and Fig. 1D
versus 1E
). In the undifferentiated tumors
(Gleason score: 9, 10) and metastases, E-cadherin was
mostly negative; and all of the cancer cells were positive for
N-cadherin albeit in two patterns, a membranous and a dotted one (Fig. 1, G, H, and I)
. The complementary
staining pattern is best illustrated in the double exposures of
N-cadherin and E-cadherin-associated immunofluorescence (Fig. 1, C and F)
.
|
, we see—besides E-cadherin- and N-cadherin-positive cell
clusters—cell-cell contacts where E-cadherin staining and N-cadherin
staining are juxtaposed (arrowheads), i.e., not
colocalized. In this case, the pattern of N-cadherin staining is
similar to that for E-cadherin. However, occasionally we found
processes in which E-cadherin and N-cadherin were expressed in the same
cell, albeit in different structures (Fig. 2B)
. This figure
also clearly illustrates that the cells that do express N-cadherin have
a marked decrease in E-cadherin immunoreactivity.
|
. Interestingly, the expression of cadherin-11 was strongly
induced in cancer areas with a typical dotted pattern (Fig. 3B)
, which was very similar to that observed for N-cadherin.
In high-grade cancers and metastases, the expression was no longer
confined to the stromal cells but was clearly observed in the cancer
cells (Fig. 3, C and D)
. Sometimes the expression
seemed to be at the stromal-epithelial interface, but coexpression of
E-cadherin/-catenin and cadherin-11 was also found in the
typical dotted pattern. In the cells coexpressing
E-cadherin/-catenin and cadherin-11, the de novo
expression of cadherin-11 was associated with a decreased expression of
E-cadherin.
|
. The membranous expression of N-cadherin increased from 5% of
low-grade cases (Gleason score: 4–6) to 50% in intermediate- and
high-grade cases (Gleason score: 7 and 8–10, respectively). This
correlation was statistically significant, as was the correlation with
decreased expression of E- cadherin (Table 2)
. In other words, there was a significant correlation between decreased
expression of E-cadherin and increased expression of N-cadherin.
Moreover, there was a trend toward a change of localization of the
cadherin complexes from a typical pattern associated with the adhesion
belt to a dotted pattern. We found the highest percentage of tumor
cells expressing N-cadherin in the dotted pattern in the metastases
(Table 1)
.
|
|
. Moreover, in 9 (60%) of 15 of the metastatic lesions, (homogeneous)
expression of cadherin-11 in the typical dotted pattern was also found.
As is illustrated by Table 4
, the most commonly observed pattern is that of mutual exclusiveness:
when E-cadherin is expressed, there is no expression of cadherin-11 in
the carcinoma cells, and when the E-cadherin staining pattern is
aberrant, cadherin-11 is expressed in a dotted pattern in the cancer
cells.
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Recently, the first reports appeared that described inappropriate expression of nonepithelial cadherins by epithelial cells as functionally related to disrupted cell-cell adhesion. A human squamous carcinoma cell line that displayed a scattered fibroblastic phenotype was found to express N-cadherin along with a decreased expression of E- and P-cadherin (24) . In addition, in several breast cancer cell lines that showed a reduced expression of E-cadherin, high levels of N-cadherin expression were found (15) . Temporary, up-regulation of expression of N-cadherin has also been suggested to play an important role in the migration of melanoma cells through the endothelium (16 , 25) . For prostate cancer, we previously found that cell lines that lack functional E-cadherin complexes do express N-cadherin and cadherin-11 (17) . In this report, for the first time, we describe the de novo expression of N-cadherin and cadherin-11 using two parameter immunofluorescence. N-cadherin was expressed in high-grade human prostate cancers, whereas no expression was found in normal prostatic tissue. The technique used, i.e., double-label immunofluorescence, allowed us to assess the expression pattern of N-cadherin and E-cadherin simultaneously. In most cases, expression of N-cadherin was observed in tumor cells that showed reduced or no staining for E-cadherin; hence, the expression seemed to be mutually exclusive. Further detailed analysis by CSLM showed that "intermediate" patterns were occasionally observed putatively representing the transition from E-cadherin to N-cadherin expression. These analyses, furthermore, illustrated a change in pattern of N-cadherin staining, which suggested a change in the adherens junction mediated by these cadherins.
The typical honeycomb pattern associated with localization in a belt-like structure disappeared, and a dotted pattern emerged. This pattern is remarkably similar to that observed for cadherin-11 in the stromal cells, and it is tempting to speculate that this dotted pattern represents an as yet poorly characterized junctional complex mediating interaction between mesenchymal cells.
Moreover, cadherin-11 has been suggested to be up-regulated during
tumor progression: it may play a role in stromal-epithelial
interactions and, thus, may be involved in migration. This would be in
agreement with the interaction of stromal and cancer cells in a subtype
of gastric cancer that is characterized by overexpression of
cadherin-11 (26)
. A role for cadherin-11 in tumor cell
invasion and metastasis is, furthermore, suggested for breast cancer:
in most invasive breast cancer cell lines, expression of cadherin-11 is
observed, whereas no expression can be detected in any noninvasive cell
line (27)
. In prostate cancer cell lines, expression of
cadherin-11 is found in those lines that have lost functional
expression of E-cadherin, attributable to loss of expression of
-catenin (17)
.
Double-label immunofluorescence analysis of cadherin-11 expression revealed no expression of cadherin-11 in nonmalignant prostate tissue. However, all of the prostate cancer specimens did show a dotted staining pattern in the stromal cells surrounding the tumor cells and at the interface of stroma and tumor cells. Further detailed analysis of the expression of cadherin-11 provided unequivocal evidence that in high-grade cancers, the tumor cells also express cadherin-11. Even more interesting is the homogeneous expression of cadherin-11 in the prostate metastatic lesions. The striking resemblance of the pattern of N-cadherin and cadherin-11 staining, i.e., in a dotted pattern, indicates that the switch in cadherin expression and concomitant change of pattern is, in fact, related to the functional interaction between cancer and stromal cells. This, in turn, could be an essential step in the metastatic cascade. Clearly, we can at this point only speculate about the biological functional relation of the cadherin switch and increased metastatic propensity. However, the significant correlation with histological grade together with the fact that we find enrichment of this effect in the metastases (i.e., the metastases show a rather homogeneous pattern for both cadherin-11 and N-cadherin expression) corroborates the hypothesis that N-cadherin/cadherin-11-positive cells have a selective advantage to metastasize. It is noteworthy, however, that up-regulation of E-cadherin in metastases has also been reported (1 , 28) , which in fact could mean that cadherin switching is a dynamic process. The functional role of reexpression of E-cadherin is yet poorly understood. Cadherin-11, also termed osteoblast(OB-)cadherin is expressed at high levels in osteoblasts, which makes it, furthermore, tempting to speculate that there is a potential role of cadherin-11 in homing toward secondary sites, particularly bone.
We, therefore, conclude that we for the first time were able to provide evidence of cadherin switching in advanced human prostate cancer. The change in pattern—resembling the pattern of cadherin expression in stromal cells—suggests a functional role of homotypic cadherin-mediated interactions, in the later stages of cancer progression.
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be
addressed, at Urology Research Laboratory, University Hospital
Nijmegen, P. O. Box 9101, 6500 HB Nijmegen, the Netherlands. Phone:
31-24-3614146; Fax: 31-24-3541222; E-mail: J.Schalken{at}uro.azn.nl 
2 The abbreviations used are: TRITC, Texas Red
isothiocyanate; CSLM, confocal scanning laser microscopy.
Received 11/19/99. Accepted 4/27/00.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-catenin expression in prostate cancer: correlation with patient survival. Cancer Res., 57: 3189-3193, 1997.-catenin and ß-catenin not of 
-catenin, in metastatic tissue from breast cancer patients. J. Pathol., 190: 15-19, 2000.[Medline]
This article has been cited by other articles:
|
|
 |
|
  C.-W. Chua, Y.-T. Chiu, H.-F. Yuen, K.-W. Chan, K. Man, X. Wang, M.-T. Ling, and Y.-C. Wong Suppression of Androgen-Independent Prostate Cancer Cell Aggressiveness by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening Platform Clin. Cancer Res., July 1, 2009; 15(13): 4322 - 4335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kashef, A. Kohler, S. Kuriyama, D. Alfandari, R. Mayor, and D. Wedlich Cadherin-11 regulates protrusive activity in Xenopus cranial neural crest cells upstream of Trio and the small GTPases Genes & Dev., June 15, 2009; 23(12): 1393 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Drake, G. Strohbehn, T. B. Bair, J. G. Moreland, and M. D. Henry ZEB1 Enhances Transendothelial Migration and Represses the Epithelial Phenotype of Prostate Cancer Cells Mol. Biol. Cell, April 15, 2009; 20(8): 2207 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Y. Huang, Z.-G. Li, H. Rus, X. Wang, P. A. Jose, and S.-Y. Chen RGC-32 Mediates Transforming Growth Factor-{beta}-induced Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Cells J. Biol. Chem., April 3, 2009; 284(14): 9426 - 9432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kucharczak, S. Charrasse, F. Comunale, J. Zappulla, B. Robert, I. Teulon-Navarro, A. Pelegrin, and C. Gauthier-Rouviere R-Cadherin Expression Inhibits Myogenesis and Induces Myoblast Transformation via Rac1 GTPase Cancer Res., August 15, 2008; 68(16): 6559 - 6568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chu, C.-J. Cheng, X. Ye, Y.-C. Lee, A. J. Zurita, D.-T. Chen, L.-Y. Yu-Lee, S. Zhang, E. T. Yeh, M. C-T. Hu, et al. Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone Mol. Cancer Res., August 1, 2008; 6(8): 1259 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shintani, Y. Fukumoto, N. Chaika, R. Svoboda, M. J. Wheelock, and K. R. Johnson Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1 J. Cell Biol., March 24, 2008; 180(6): 1277 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Wheelock, Y. Shintani, M. Maeda, Y. Fukumoto, and K. R. Johnson Cadherin switching J. Cell Sci., March 15, 2008; 121(6): 727 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pittet, K. Lee, A. J. Kulik, J.-J. Meister, and B. Hinz Fibrogenic fibroblasts increase intercellular adhesion strength by reinforcing individual OB-cadherin bonds J. Cell Sci., March 15, 2008; 121(6): 877 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chung, A. K. Y. Lam, J. M. Luk, S. Law, K.-W. Chan, P.-Y. Lee, and J. Wong Altered E-Cadherin Expression and p120 Catenin Localization in Esophageal Squamous Cell Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3260 - 3267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Buijs, C. A. Rentsch, G. van der Horst, P. G.M. van Overveld, A. Wetterwald, R. Schwaninger, N. V. Henriquez, P. ten Dijke, F. Borovecki, R. Markwalder, et al. BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo Am. J. Pathol., September 1, 2007; 171(3): 1047 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hotz, M. Arndt, S. Dullat, S. Bhargava, H.-J. Buhr, and H. G. Hotz Epithelial to Mesenchymal Transition: Expression of the Regulators Snail, Slug, and Twist in Pancreatic Cancer Clin. Cancer Res., August 15, 2007; 13(16): 4769 - 4776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shukla, G. T. MacLennan, C. A. Flask, P. Fu, A. Mishra, M. I. Resnick, and S. Gupta Blockade of {beta}-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice Cancer Res., July 15, 2007; 67(14): 6925 - 6935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C-K. Chung, S. Zhou, L. Liao, J. C.-Y. Tien, N. M. Greenberg, and J. Xu Genetic Ablation of the Amplified-in-Breast Cancer 1 Inhibits Spontaneous Prostate Cancer Progression in Mice Cancer Res., June 15, 2007; 67(12): 5965 - 5975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Chen and Z.-Z. Ma N-Cadherin Expression in a Rat Model of Retinal Detachment and Reattachment Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1832 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Alonso, L. Tracey, P. Ortiz, B. Perez-Gomez, J. Palacios, M. Pollan, J. Linares, S. Serrano, A. I. Saez-Castillo, L. Sanchez, et al. A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis Cancer Res., April 1, 2007; 67(7): 3450 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. G. Kan, M. P. Stemmler, D. Junghans, B. Kanzler, W. N. de Vries, M. Dominis, and R. Kemler Gene replacement reveals a specific role for E-cadherin in the formation of a functional trophectoderm Development, January 1, 2007; 134(1): 31 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shintani, M. A. Hollingsworth, M. J. Wheelock, and K. R. Johnson Collagen I Promotes Metastasis in Pancreatic Cancer by Activating c-Jun NH2-Terminal Kinase 1 and Up-regulating N-Cadherin Expression Cancer Res., December 15, 2006; 66(24): 11745 - 11753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takkunen, R. Grenman, M. Hukkanen, M. Korhonen, A. Garcia de Herreros, and I. Virtanen Snail-dependent and -independent Epithelial-Mesenchymal Transition in Oral Squamous Carcinoma Cells J. Histochem. Cytochem., November 1, 2006; 54(11): 1263 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Moreno-Bueno, E. Cubillo, D. Sarrio, H. Peinado, S. M. Rodriguez-Pinilla, S. Villa, V. Bolos, M. Jorda, A. Fabra, F. Portillo, et al. Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition Cancer Res., October 1, 2006; 66(19): 9543 - 9556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.M. de Yzaguirre, J.S. Hernandez, P.F. Navarro, P.L. Nieva, M. Herranz, M.F. Fraga, M. Esteller, A. Juarranz, and J. Fernandez-Piqueras Epigenetic silencing of E- and N-cadherins in the stroma of mouse thymic lymphomas Carcinogenesis, May 1, 2006; 27(5): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lascombe, A. Clairotte, S. Fauconnet, S. Bernardini, H. Wallerand, B. Kantelip, and H. Bittard N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin. Cancer Res., May 1, 2006; 12(9): 2780 - 2787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Kiener, C. S. Stipp, P. G. Allen, J. M.G. Higgins, and M. B. Brenner The Cadherin-11 Cytoplasmic Juxtamembrane Domain Promotes {alpha}-Catenin Turnover at Adherens Junctions and Intercellular Motility Mol. Biol. Cell, May 1, 2006; 17(5): 2366 - 2376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Alexander, N. L. Tran, H. Rekapally, C. E. Summers, C. Glackin, and R. L. Heimark N-cadherin Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1. Cancer Res., April 1, 2006; 66(7): 3365 - 3369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Azuma, S. Ehata, H. Miyazaki, T. Watabe, O. Maruyama, T. Imamura, T. Sakamoto, S. Kiyama, Y. Kiyama, T. Ubai, et al. Effect of Smad7 Expression on Metastasis of Mouse Mammary Carcinoma JygMC(A) Cells J Natl Cancer Inst, December 7, 2005; 97(23): 1734 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J.M. Best, J. W. Gillespie, Y. Yi, G. V.R. Chandramouli, M. A. Perlmutter, Y. Gathright, H. S. Erickson, L. Georgevich, M. A. Tangrea, P. H. Duray, et al. Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy Clin. Cancer Res., October 1, 2005; 11(19): 6823 - 6834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Qi, N. Chen, J. Wang, and C.-H. Siu Transendothelial Migration of Melanoma Cells Involves N-Cadherin-mediated Adhesion and Activation of the {beta}-Catenin Signaling Pathway Mol. Biol. Cell, September 1, 2005; 16(9): 4386 - 4397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Thompson, D. F. Newgreen, and D. Tarin Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition? Cancer Res., July 15, 2005; 65(14): 5991 - 5995. [Full Text] [PDF]
|
|
|
|
|
|
K. Taniuchi, H. Nakagawa, M. Hosokawa, T. Nakamura, H. Eguchi, H. Ohigashi, O. Ishikawa, T. Katagiri, and Y. Nakamura Overexpressed P-Cadherin/CDH3 Promotes Motility of Pancreatic Cancer Cells by Interacting with p120ctn and Activating Rho-Family GTPases Cancer Res., April 15, 2005; 65(8): 3092 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Valencia, J. M.G. Higgins, H. P. Kiener, D. M. Lee, T. A. Podrebarac, C. C. Dascher, G. F.M. Watts, E. Mizoguchi, B. Simmons, D. D. Patel, et al. Cadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like Synoviocytes J. Exp. Med., December 20, 2004; 200(12): 1673 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Christiansen and A. K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hinz, P. Pittet, J. Smith-Clerc, C. Chaponnier, and J.-J. Meister Myofibroblast Development Is Characterized by Specific Cell-Cell Adherens Junctions Mol. Biol. Cell, September 1, 2004; 15(9): 4310 - 4320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Johnson, C. S. Theisen, K. R. Johnson, and M. J. Wheelock R-cadherin Influences Cell Motility via Rho Family GTPases J. Biol. Chem., July 23, 2004; 279(30): 31041 - 31049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakajima, R. Doi, E. Toyoda, S. Tsuji, M. Wada, M. Koizumi, S. S. Tulachan, D. Ito, K. Kami, T. Mori, et al. N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma Clin. Cancer Res., June 15, 2004; 10(12): 4125 - 4133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1242 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Roitbak, C. J. Ward, P. C. Harris, R. Bacallao, S. A. Ness, and A. Wandinger-Ness A Polycystin-1 Multiprotein Complex Is Disrupted in Polycystic Kidney Disease Cells Mol. Biol. Cell, March 1, 2004; 15(3): 1334 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Green, G. Francia, C. Isidoro, and R. S. Kerbel Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro Mol. Cancer Ther., February 1, 2004; 3(2): 149 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mareel and A. Leroy Clinical, Cellular, and Molecular Aspects of Cancer Invasion Physiol Rev, April 1, 2003; 83(2): 337 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Van Aken, O. De Wever, L. Van Hoorde, E. Bruyneel, J.-J. De Laey, and M. M. Mareel Invasion of Retinal Pigment Epithelial Cells: N-cadherin, Hepatocyte Growth Factor, and Focal Adhesion Kinase Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 463 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Green, M. C. I. Karlsson, J. V. Ravetch, and R. S. Kerbel Disruption of Cell-Cell Adhesion Enhances Antibody-dependent Cellular Cytotoxicity: Implications for Antibody-based Therapeutics of Cancer Cancer Res., December 1, 2002; 62(23): 6891 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lin, Y. Nagai, R. Sladek, Y. Bastien, J. Ho, K. Petrecca, G. Sotiropoulou, E. P. Diamandis, T. J. Hudson, and J. H. White Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation Mol. Endocrinol., June 1, 2002; 16(6): 1243 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Van Aken, P. Papeleu, Patrick De Potter, E. Bruyneel, J. Philippe, S. Seregard, A. Kvanta, J.-J. De Laey, and M. M. Mareel Structure and Function of the N-Cadherin/Catenin Complex in Retinoblastoma Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zeitvogel, R. Baumann, and A. Starzinski-Powitz Identification of an Invasive, N-Cadherin-Expressing Epithelial Cell Type in Endometriosis Using a New Cell Culture Model Am. J. Pathol., November 1, 2001; 159(5): 1839 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Rieger-Christ, J A Pezza, J M Dugan, J W Braasch, K S Hughes, and I C Summerhayes Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas Mol. Pathol., April 1, 2001; 54(2): 91 - 97. [Abstract] [Full Text]
|
|
|
|
|
|
L. Kotelevets, J. van Hengel, E. Bruyneel, M. Mareel, F. van Roy, and E. Chastre The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness J. Cell Biol., December 24, 2001; 155(7): 1129 - 1136. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
